Citadel Advisors’s AMAG Pharmaceuticals AMAG Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q4 | – | Sell |
-134,552
| Closed | -$1.26M | – | 11861 |
|
|
2020
Q3 | $1.26M | Sell |
134,552
-141,614
| -51% | -$1.35M | ﹤0.01% | 5603 |
|
|
2020
Q2 | $2.11M | Buy |
276,166
+104,951
| +61% | +$803K | ﹤0.01% | 4473 |
|
|
2020
Q1 | $1.06M | Buy |
171,215
+129,666
| +312% | +$1.14M | ﹤0.01% | 5236 |
|
|
2019
Q4 | $506K | Buy |
+41,549
| New | +$454K | ﹤0.01% | 6794 |
|
|
2019
Q3 | – | Sell |
-12,344
| Closed | -$130K | – | 10042 |
|
|
2019
Q2 | $123K | Sell |
12,344
-22,769
| -65% | -$246K | ﹤0.01% | 8454 |
|
|
2019
Q1 | $452K | Sell |
35,113
-45,672
| -57% | -$680K | ﹤0.01% | 6958 |
|
|
2018
Q4 | $1.23M | Sell |
80,785
-27,039
| -25% | -$515K | ﹤0.01% | 4994 |
|
|
2018
Q3 | $2.16M | Buy |
107,824
+87,916
| +442% | +$2M | ﹤0.01% | 4282 |
|
|
2018
Q2 | $388K | Sell |
19,908
-44,734
| -69% | -$990K | ﹤0.01% | 6786 |
|
|
2018
Q1 | $1.3M | Sell |
64,642
-416,487
| -87% | -$7.05M | ﹤0.01% | 4405 |
|
|
2017
Q4 | $6.38M | Buy |
+481,129
| New | +$7.25M | ﹤0.01% | 2186 |
|
|
2017
Q3 | – | Sell |
-1,164,079
| Closed | -$21.7M | – | 8291 |
|
|
2017
Q2 | $21.4M | Buy |
1,164,079
+1,146,232
| +6,423% | +$22.7M | 0.02% | 962 |
|
|
2017
Q1 | $402K | Buy |
+17,847
| New | +$427K | ﹤0.01% | 5397 |
|
|
2016
Q4 | – | Sell |
-89,943
| Closed | -$2.69M | – | 8102 |
|
|
2016
Q3 | $2.21M | Buy |
+89,943
| New | +$2.25M | ﹤0.01% | 2852 |
|
|
2016
Q2 | – | Sell |
-20,743
| Closed | -$476K | – | 7646 |
|
|
2016
Q1 | $485K | Sell |
20,743
-420,257
| -95% | -$9.97M | ﹤0.01% | 4457 |
|
|
2015
Q4 | $13.3M | Buy |
441,000
+357,504
| +428% | +$11.6M | 0.01% | 1076 |
|
|
2015
Q3 | $3.32M | Buy |
83,496
+44,181
| +112% | +$2.74M | ﹤0.01% | 2346 |
|
|
2015
Q2 | $2.71M | Buy |
39,315
+29,402
| +297% | +$1.85M | ﹤0.01% | 2696 |
|
|
2015
Q1 | $542K | Buy |
9,913
+8,385
| +549% | +$400K | ﹤0.01% | 4778 |
|
|
2014
Q4 | $65K | Sell |
1,528
-19,800
| -93% | -$715K | ﹤0.01% | 7003 |
|
|
2014
Q3 | $680K | Buy |
+21,328
| New | +$455K | ﹤0.01% | 4207 |
|
|
2014
Q2 | – | Sell |
-36,824
| Closed | -$680K | – | 8463 |
|
|
2014
Q1 | $713K | Buy |
36,824
+4,161
| +13% | +$88.4K | ﹤0.01% | 3859 |
|
|
2013
Q4 | $793K | Buy |
32,663
+31,162
| +2,076% | +$733K | ﹤0.01% | 3466 |
|
|
2013
Q3 | $32K | Buy |
1,501
+1,057
| +238% | +$25K | ﹤0.01% | 6010 |
|
|
2013
Q2 | $10K | Buy |
+444
| New | +$9.78K | ﹤0.01% | 6243 |
|
Citadel Advisors's AMAG Position: Q4 2020 in Review
Citadel Advisors sold out of AMAG Pharmaceuticals (AMAG) in Q4 2020, closing a stake of 134,552 shares — an estimated $1.26M sold.
Citadel Advisors first reported a position in AMAG in Q2 2013 and held it in 25 quarters. The position peaked at $21.4M in Q2 2017. 1 fund tracked by Wall St. Rank holds AMAG as of Q4 2020.
- Citadel Advisors reported no remaining AMAG Pharmaceuticals position as of Q4 2020 after selling out during the quarter.
- Citadel Advisors sold 134,552 AMAG Pharmaceuticals shares in Q4 2020, an estimated $1.26M.
- Citadel Advisors first reported a position in AMAG Pharmaceuticals in Q2 2013 and held it in 25 quarters.
- Citadel Advisors's AMAG Pharmaceuticals position peaked at $21.4M in Q2 2017.
- 1 fund tracked by Wall St. Rank held AMAG Pharmaceuticals as of Q4 2020.
Based on Citadel Advisors's 13F filing for Q4 2020, filed 16 Feb 2021.